1GLOBAL and Verint Partner to Deliver Enhanced Cloud-Based Mobile Compliance Recording Solutions for Financial Trading Organisations Worldwide
1GLOBAL, a top-tier mobile virtual network operator (MVNO) today announced a strategic partnership with Verint to transform compliance across the financial services and trading sectors to upgrade mobile compliance recording solutions for financial institutions throughout the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711072434/en/
1GLOBAL and Verint partner to offer enhanced Mobile Compliance Recording worldwide (Graphic: Business Wire)
Through this new alliance, 1GLOBAL will now provide all of its global clients with trusted cloud-based recording solutions supported by Verint Financial Compliance. Professionals with compliance obligations can increase their productivity and further their capabilities with voice transcription featuring keyword searching, alerting and meeting summaries.
1GLOBAL clients will also be able to reliably conform with compliance and trade surveillance policies under MiFID II, Dodd-Frank, and MAR / MAD II (among others) to help avoid non-compliance fines and penalties. This new toolset will accelerate compliance audits and easily provide regulatory agencies with complete records of trade-related interactions in a timely manner. Building in these efficiencies reduces costs for financial organizations by leveraging simplified administration, streamlined conversation retrieval, automated rules, and a wide set of external storage integrations on one single contract.
"Partnering with Verint enables us to offer our customers access to the most innovative cloud-based recording solutions on the market,” said Siobhan Thompson, Head of 1GLOBAL Compliance. “Compliance in the cloud is key to 1GLOBAL's strategy. Our partnership with Verint and their VFC platform for our cloud hosting is a testament to that. Verint's cutting edge technology coupled with 1GLOBAL's leading mobile recording capabilities provides customers with assured compliance capabilities as well as increased productivity and analytics.”
“Combining the 1GLOBAL mobile voice and SMS capture capability with the core Verint solution is a critical part of the joint strategy to align all communications into a user-centric view,” says Verint’s John Bourne, Senior VP Global Channels & Alliances. “The integration will provide customers with more control, increased data completeness and the ability to proactively expose compliance anomalies.”
More information on 1GLOBAL’s compliance solution can be found at https://www.1global.com/compliance
About 1GLOBAL
1GLOBAL are market leaders in digital transformation, offering a comprehensive suite of products engineered to facilitate global connectivity at any scale.From truly borderless global business roaming to financial compliance and recording, each solution represents a commitment to excellence.
Started in 2022 by Hakan Koç, co-founder and former co-CEO of AUTO1 Group, 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognised GSMA-accredited global mobile network. Headquartered in London, with an R&D hub in Lisbon, they have now grown to include over 400 employees across 12 countries and are a fully regulated MVNO in nine of them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711072434/en/
Contacts
press@1global.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom